Status:

COMPLETED

Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Diabetes

Eligibility:

MALE

18-45 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate whether the within-subject variation in duration of action and time-action profile of glargine measured by isoglycemic clamp will be below prespecified levels.

Eligibility Criteria

Inclusion

  • Part 1:
  • Patient is a male between 18 to 45 years of age (inclusive) at the prestudy (screening) visit
  • Patient has a clinical diagnosis of type 1 diabetes
  • Patient must have been treated with insulin since diagnosis and be on a stable dose of insulin
  • Patient has a Body Mass Index (BMI) of \<=27 kg/m2 and \>18 kg/m2
  • Patient has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months
  • Part 2:
  • Subject is a male between 18 to 45 years of age at the prestudy (screening) visit
  • Subject has a Body Mass Index (BMI) of \<=25 kg/m\^2
  • Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion

  • Part 1:
  • Patient has a history of stroke, chronic seizures, or major neurological disorder
  • Patient has currently active and untreated clinically significant endocrine, cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary abnormalities or diseases
  • Patient has a history of hypertension requiring treatment
  • Patient has a history of neoplastic disease within the past 5 years
  • Patient is currently being treated with, or has a history of treatment with any oral antihyperglycemic agent
  • Patient has a history of significant multiple and/or severe allergies
  • Part 2:
  • Subject has a history of stroke, chronic seizures, or major neurological disorder
  • Subject has a history of hypertension requiring treatment
  • Subject has a history of neoplastic disease within the past 5 years
  • Subject has history of diabetes (Type 1, Type 2 or steroid-induced) or family history of diabetes mellitus
  • Subject has a history of hypersensitivity to glargine or any of its inactive ingredients

Key Trial Info

Start Date :

August 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT01152242

Start Date

August 1 2010

End Date

May 1 2012

Last Update

July 23 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.